Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

RNase-Fc fusion protein RSLV-132

A fusion protein composed of a full-length, catalytically active human ribonuclease (RNase) moiety fused to the amino-terminus of an engineered human immunoglobulin G1 (IgG1) Fc domain, with potential anti-inflammatory and immunomodulatory activities. Upon administration, RNase-Fc fusion protein RSLV-132 catalyzes the degradation of extracellular RNA circulating in the blood and removes them from the blood circulation. This may prevent the presentation of RNA autoantigens to the immune system and reduce inflammation. Circulating RNA-containing autoantigens and autoantibodies drive chronic inflammation in autoimmune diseases such as lupus and Sjogren's syndrome. Both viral RNA and RNA-containing autoantibodies in the blood circulation may be associated with inflammation in post-acute sequelae of SARS-CoV-2 infection (PASC) or long COVID.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:RSLV 132
RSLV-132
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search